Clinical Trial Details
| Trial ID: | L5556 |
| Source ID: | NCT01467375 |
| Associated Drug: | Biphasic Insulin Aspart |
| Title: | Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: biphasic insulin aspart |
| Outcome Measures: | Primary: Occurrence of adverse events|Frequency of hypoglycaemic episodes | Secondary: HbA1c (glycosylated haemoglobin) |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 89 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2001-01-08 |
| Completion Date: | 2004-10-22 |
| Results First Posted: | |
| Last Update Posted: | 2017-02-24 |
| Locations: | Novo Nordisk Investigational Site, Broadmeadow, New South Wales, 2292, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, 3052, Australia|Novo Nordisk Investigational Site, Ashford, 5035, Australia|Novo Nordisk Investigational Site, Auchenflower, 4066, Australia|Novo Nordisk Investigational Site, Launceston, 7250, Australia|Novo Nordisk Investigational Site, Nowra, 2540, Australia|Novo Nordisk Investigational Site, Ringwood, 3134, Australia|Novo Nordisk Investigational Site, Rooty Hill, 2766, Australia|Novo Nordisk Investigational Site, Hull, J8Y 1W1, Canada|Novo Nordisk Investigational Site, London, N6A 4L6, Canada|Novo Nordisk Investigational Site, Quebec, G1V 4G2, Canada|Novo Nordisk Investigational Site, Saskatoon, S7N 0W8, Canada |
| URL: | https://clinicaltrials.gov/show/NCT01467375 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|